Advertisement

Topics

Proteostasis Therapeutics shares tumble on disappointing data for cystic fibrosis triplet therapy

06:34 EDT 25 Mar 2019 | Proactive Investors

The triplet therapy for cystic fibrosis patients failed to show a significant improvement in the measure of a lung function referred to as ppFEV1

Original Article: Proteostasis Therapeutics shares tumble on disappointing data for cystic fibrosis triplet therapy

NEXT ARTICLE

More From BioPortfolio on "Proteostasis Therapeutics shares tumble on disappointing data for cystic fibrosis triplet therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...